Fosamprenavir:回顾其使用抗逆转录病毒therapy-naive艾滋病毒感染患者的管理。

文章的细节

引用
复制到剪贴板

查普曼TM Plosker GL,佩里厘米

Fosamprenavir:回顾其使用抗逆转录病毒therapy-naive艾滋病毒感染患者的管理。

药。2004;64 (18):2101 - 24。

PubMed ID
15341507 (在PubMed
]
文摘

Fosamprenavir (GW433908 Lexiva Telzir)是一种口服药物前体的蛋白酶抑制剂(PI) amprenavir,减少日常丸负担。结合其他抗逆转录病毒药物,Fosamprenavir表示治疗HIV感染的患者,特别是那些之前没有接受抗逆转录病毒治疗。病毒载量下降至少一样伟大与nelfinavir-based fosamprenavir-based方案与实现方案在两个大,48周,随机、多中心试验在抗逆转录病毒therapy-naive艾滋病毒感染患者。在整洁的研究中,更多的病人接受每天fosamprenavir结合abacavir和拉米夫定实现艾滋病毒RNA水平< 400拷贝/毫升比接受类似的nelfinavir-based方案。独奏的结果研究显示类似的减少病毒载量在病人每日一次的双fosamprenavir和对待每天奈非那韦,在结合每天abacavir和拉米夫定。在这两个试验,病毒学失败率至少两倍的nelfinavir-based方案时fosamprenavir-based方案。Fosamprenavir在临床试验一般耐受性良好。fosamprenavir患者中最常见的不良事件,有或没有例如+ abacavir和拉米夫定是腹泻、恶心、呕吐、腹痛、药物过敏和皮疹。fosamprenavir-based治疗腹泻的发病率要低得多,比整洁独奏nelfinavir-based治疗试验。阻力与amprenavir fosamprenavir是一致的。 Amprenavir-resistant viral isolates from patients experiencing treatment failure with fosamprenavir-based therapy in the NEAT study showed little or no cross-resistance to several other PIs, and protease mutations commonly selected for by various other PIs were not observed. In the SOLO study, protease resistance mutations were not observed in viral isolates from patients experiencing treatment failure with ritonavir-boosted fosamprenavir-based therapy. In conclusion, fosamprenavir-based regimens have shown good antiviral efficacy and are generally well tolerated in antiretroviral therapy-naive patients with HIV infection. Available data on the resistance profile of the drug suggest that it may be used early in the course of therapy without compromising a range of future treatment options. The relatively low pill burden and lack of food restrictions with fosamprenavir may improve adherence to therapy. Further studies are needed to compare fosamprenavir with other PIs and to establish the long-term efficacy of fosamprenavir-based regimens. In conclusion, fosamprenavir appears to be a promising agent for the treatment of antiretroviral therapy-naive patients with HIV infection.

DrugBank数据引用了这篇文章

药物